About
Technology
Issues
FAQ
Links
Official Page
Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.